Sarah Ketterer's AZN Position Overview
Sarah Ketterer (via Causeway Capital Management LLC) currently holds 1.1M shares of AstraZeneca PLC (AZN) worth $81.89 M, representing 1.08% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Sarah Ketterer has maintained a strategic position in AZN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 341.4K shares. Largest reduction occurred in Q2 2022, reducing 74.3K shares.
Analysis based on 13F filings available since 2013 Q2
Sarah Ketterer's AstraZeneca PLC (AZN) Holding Value Over Time
Track share changes against reported price movement
Quarterly AstraZeneca PLC (AZN) Trades by Sarah Ketterer
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2021 | +169,783 | New Buy | 169,783 | $59.90 |
| Q3 2021 | +177,228 | Add 104.39% | 347,011 | $60.06 |
| Q4 2021 | -16,539 | Reduce 4.77% | 330,472 | $58.25 |
| Q1 2022 | +77,683 | Add 23.51% | 408,155 | $66.34 |
| Q2 2022 | -74,258 | Reduce 18.19% | 333,897 | $66.07 |
| Q3 2022 | -29,284 | Reduce 8.77% | 304,613 | $54.84 |
| Q4 2022 | -15,993 | Reduce 5.25% | 288,620 | $67.80 |
| Q1 2023 | +35,083 | Add 12.16% | 323,703 | $69.41 |
| Q2 2023 | -59,357 | Reduce 18.34% | 264,346 | $71.57 |
| Q3 2023 | +90,875 | Add 34.38% | 355,221 | $67.72 |
| Q4 2023 | +105,501 | Add 29.70% | 460,722 | $67.35 |
| Q1 2024 | +35,754 | Add 7.76% | 496,476 | $67.75 |
| Q2 2024 | -45,888 | Reduce 9.24% | 450,588 | $77.99 |
| Q3 2024 | +39,851 | Add 8.84% | 490,439 | $77.91 |
| Q4 2024 | +341,431 | Add 69.62% | 831,870 | $65.52 |
| Q1 2025 | +26,017 | Add 3.13% | 857,887 | $73.50 |
| Q2 2025 | +95,561 | Add 11.14% | 953,448 | $69.88 |
| Q3 2025 | +113,923 | Add 11.95% | 1.07 M | $76.72 |
Sarah Ketterer's AstraZeneca PLC Investment FAQs
Sarah Ketterer first purchased AstraZeneca PLC (AZN) in Q2 2021, acquiring 169,783 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Sarah Ketterer has held AstraZeneca PLC (AZN) for 18 quarters since Q2 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Sarah Ketterer's largest addition to AstraZeneca PLC (AZN) was in Q4 2024, adding 831,870 shares worth $54.5 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Sarah Ketterer's firm, Causeway Capital Management LLC, owns 1,067,371 shares of AstraZeneca PLC (AZN), valued at approximately $81.89 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, AstraZeneca PLC (AZN) represents approximately 1.08% of Sarah Ketterer's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Sarah Ketterer's peak holding in AstraZeneca PLC (AZN) was 1,067,371 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.